scorecardresearch
Follow Us:
Monday, July 04, 2022

WHO panel issues strong advice against hydroxychloroquine for COVID-19

This "strong recommendation", the experts said, is based on high-certainty evidence from six randomised controlled trials involving more than 6,000 participants both with and without known exposure to COVID-19.

By: Reuters |
March 2, 2021 10:44:04 am
Solidarity Trial, WHO Solidarity Trial, Remdesivir, WHO on Remdesivir, Remdesivir Covid 19, WHO on Covid drugs, hydroxychloroquine, lopinavir/ritonavir, interferon, Indian ExpressA bottle of hydroxychloroquine tablets in Texas City, Texas. (AP Photo/David J. Phillip, File)

The drug hydroxychloroquine, once touted by Donald Trump as a pandemic “game-changer”, should not be used to prevent COVID-19 and has no meaningful effect on patients already infected, a World Health Organization expert panel said on Tuesday.

The anti-inflammatory drug should not be used in the fight against the pandemic, the WHO’s Guideline Development Group (GDG) expert panel wrote in the BMJ British medical journal, and is “not worthwhile” exploring in further research studies of possible COVID-19 treatments.

This “strong recommendation”, the experts said, is based on high-certainty evidence from six randomised controlled trials involving more than 6,000 participants both with and without known exposure to COVID-19.

Former U.S. President Trump said last March that hydroxychloroquine could be a game-changer in the coronavirus pandemic. He also said he was taking it himself, even after the U.S. medicines regulator, the Food and Drug Administration (FDA), advised that its efficacy and safety were unproven.

Best of Express Premium
UPSC Essentials: Key terms of the past weekPremium
ExplainSpeaking: Despite the fall, are Indian stock markets still overval...Premium
‘Peter Brook tried to destroy, recreate us. I wasn’t willing to be destro...Premium
In Gujarat, Covid crisis brings estranged couples together for second chancePremium

But the WHO’s experts said they now “judged that almost all people would not consider this drug worthwhile”.

“The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent COVID-19,” they wrote.

The WHO noted in a statement that the recommendation is a so-called “living guideline” on potential drugs for COVID-19.

The guidelines, which can be updated as new evidence emerges, are designed to advise doctors and healthcare providers on managing the respiratory disease and help them make better decisions for patients.

Express Explained Go beyond the news. Understand the headlines with our Explained stories

📣 Join our Telegram channel (The Indian Express) for the latest news and updates

For all the latest World News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement